In summary, the involvement of RET in the pathogenesis of BC and in the development of ER±+ tumors is confirmed by several independent studies and a strong body of evidence confirms that RET might be an effective target to enhance sensitivity of BC to antitumoral therapy and to overcome drug resistance. This evidence concerns the gene RET and breast cancer.